We seek to make antiretroviral drugs more affordable by removing barriers to market competition.
High prices exclude people from HIV treatment
The high price of antiretroviral drugs means many people in middle-income countries cannot get the treatment they need. Our four focus countries all pay more than US$3,000 per patient, per year, for essential second and third-line regimens of antiretroviral drugs. Governments in middle-income countries have to cover these costs themselves, with little support from international donors.
Unwarranted patents keep prices high
Pharmaceutical companies can charge high prices as they have secured patents to prevent competition from generic manufacturers. While some patents are valid, often they are unmerited. In some cases, the price is up to fifty times higher than the lowest available generic prices.
Our interventions to make medicines affordable
We have four key strategies to make medicines more affordable. See summaries of our strategies and follow the links below.
We monitor trade negotiations, and challenge attempts to protect intellectual property at the expense of public health.
Law and policy reform
We advocate for change in laws and policies to protect access to medicines and public health.
We challenge applications for unmerited patents on antiretroviral drugs to force companies to compete and reduce the price of their drugs.
We encourage governments to fully exercise their right to suspend patent protection, when it threatens access to medicines.